Thomson Reuters Helps Brazil's Institute for Applied Economic Research Identify New Generic Drug Opportunities

Brazil - Português

Newport provides Brazilian government with comprehensive pharmaceutical data

News provided by

Jan 26, 2012, 09:00 ET

PHILADELPHIA, Jan. 26, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters announced an agreement with Brazil's Institute for Applied Economic Research (IPEA). This partnership provides IPEA's Direction of Sectorial Studies and Policies for Innovation, Regulation and Infrastructure (DISET) branch with access to the Newport suite of products, including generic pharmaceutical intelligence and tools for sourcing global pharmaceutical ingredients.

IPEA, a federal public foundation linked to the Strategic Affairs Secretariat of the Brazilian Presidency, provides technical and institutional support to the government for the development of public policies and development programs in Brazil. Within IPEA, DISET performs studies and evaluates public policies on science, technology and innovation.

DISET will use Newport to find new opportunities to improve Brazil's national pharmaceutical infrastructure. In addition to the extensive generic drug information available through the Newport suite of products, the group will have access to the Newport Generic Deals module, providing seamless integration of nearly 10,000 generic industry deals since 1999.

"We are enthusiastic about the Newport database," said Professor Eduardo Fiuza, member of the Board of Sector Studies for DISET. "I have never seen so much information about and capabilities for the generic drug market assembled in one single database. It will certainly speed up our data search and contribute to our extensive inquiry on the Brazilian pharmaceutical market."

"This is an exciting time in the evolution of Brazil's pharmaceutical development, and we are pleased to partner with DISET to ensure it meets its goals," said Jon Brett-Harris, executive vice president at Thomson Reuters. "Newport is an essential tool for uncovering new opportunities in the generic drug market, while the M&A data in our Deals module will pave the way for further economic progress."

More information is available here.

About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.

SOURCE Thomson Reuters